- Home
- TRMD vs DYN Comparison
TRMD vs DYN Comparison
Compare TRMD & DYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRMD | DYN |
|---|---|---|
| Founded | 1889 | 1984 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.1B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRMD | DYN |
|---|---|---|
| Price | $29.68 | $17.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 14 |
| Target Price | $35.00 | ★ $37.00 |
| AVG Volume (30 Days) | 906.2K | ★ 1.4M |
| Earning Date | 05-13-2026 | 05-04-2026 |
| Dividend Yield | ★ 6.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.61 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.37 | $8.25 |
| 52 Week High | $35.33 | $25.00 |
Technical Indicators
Market Signals| Indicator | TRMD | DYN |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 48.35 |
| Support Level | $29.15 | $16.46 |
| Resistance Level | $31.76 | $19.54 |
| Average True Range (ATR) | 0.81 | 1.03 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 43.09 | 33.77 |
Price Performance
Historical ComparisonAbout TRMD TORM plc
TORM plc operates as a shipping company mainly owning and operating a fleet of product tankers. It is engaged in the transportation of refined oil products and clean petroleum products, including gasoline, jet fuel, naphtha and diesel oil. The Company operates through two segments: the Tanker segment and the Marine Engineering segment, deriving the majority of its revenue from the Tanker segment.
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.